Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cotadutide in Japanese Obese T2DM
NCT04208620Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2020
- Primary completion
- Jul 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and obesity comparing Cotadutide with Placebo (2 arms). Primary endpoints: Incidence of treatment-emergent adverse events, Incidence of treatment-emergent serious adverse events and 3 more. Started Jan 2020; status: completed.
02
Drugs
cotadutide
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT04208620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04208620.